ClinicalTrials.Veeva

Menu
Y

Yamanashi Prefectural Central Hospital | Yamanashi, Japan

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Filgotinib
Glibenclamide
Apremilast
BIIB093
Risankizumab
Pembrolizumab
Etrasimod
ABT-494
Guselkumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 11 total trials

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC)

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Enrolling
Colitis, Ulcerative
Biological: JNJ-78934804
Drug: Placebo

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Invitation-only
Vitiligo
Drug: Placebo
Drug: Upadacitinib

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting
Ulcerative Colitis
Drug: Etrasimod

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Enrolling
Warm Autoimmune Hemolytic Anemia
Drug: M281
Drug: Placebo

The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to se...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: Efavaleukin alfa

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Datopotamab Deruxtecan
Drug: Pembrolizumab

Trial sponsors

AbbVie logo
Amgen logo
Janssen (J&J Innovative Medicine) logo
Daiichi Sankyo logo
G
Pfizer logo
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems